Screening Group, International Agency for Research on Cancer, Lyon, France.
Chittaranjan National Cancer Institute, Kolkata, West Bengal, India.
Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:73-85. doi: 10.1016/j.bpobgyn.2017.08.012. Epub 2017 Sep 6.
Cervical cancer affects women in their reproductive ages. Screening is an important secondary prevention strategy. The long process of carcinogenic transformation from human papillomavirus (HPV) infection to invasive cancer provides ample opportunities to detect the disease at a stage when treatment is highly effective. Suitable screening tests are cytology, visual inspection after acetic acid application and HPV detection tests. Evidence of effectiveness of the tests to reduce cervical cancer mortality and the cost-effectiveness of screening programs have been demonstrated. Cervical intraepithelial neoplasia grade 2 and grade 3 are the high-grade cervical cancer precursors and need to be treated. Treatment is safe and effective with ablative or excisional techniques. The World Health Organization recommends screening women at least once in a lifetime between 30 and 49 years of age and ensuring effective treatment of the detected abnormalities. Combination of HPV vaccination and population-based screening will be instrumental in eliminating cervical cancer.
宫颈癌影响处于生育期的女性。筛查是一种重要的二级预防策略。从人乳头瘤病毒(HPV)感染到浸润性癌的致癌转化过程漫长,为在治疗效果极高的阶段发现疾病提供了充足的机会。合适的筛查试验包括细胞学检查、醋酸应用后肉眼观察和 HPV 检测。已经证明了这些试验在降低宫颈癌死亡率方面的有效性和筛查计划的成本效益。宫颈上皮内瘤变 2 级和 3 级是高级别宫颈癌前病变,需要治疗。消融或切除技术的治疗安全有效。世界卫生组织建议 30 至 49 岁的女性至少每两年筛查一次,并确保对发现的异常进行有效治疗。HPV 疫苗接种和基于人群的筛查相结合将有助于消除宫颈癌。